Source comparison
Thymosin Alpha-1 Before and After: Research Comparison
Research outcomes vary significantly based on baseline immune status, concurrent therapies, and endpoint measurement timing. The following comparison summarizes published research across major application areas, highlighting measurable before and after immune
This comparison does not assign a generated winner or score.
- Research outcomes vary significantly based on baseline immune status, concurrent therapies, and endpoint measurement timing. The following comparison summarizes published research across major application areas, highlighting measurable before and after immune marker changes.
- Hepatitis B Viral Load
- HBV DNA >10^5 copies/mL, normal CD4 counts
- HBV DNA reduction
- 1.8 log reduction vs 0.9 log antiviral alone
- 24 weeks at 1.6mg twice weekly
- Thymosin Alpha-1 enhances antiviral efficacy through immune restoration—viral clearance rates double when combined with nucleoside analogs
- Cancer Immunotherapy (Melanoma)
- Post-chemotherapy CD4 <350 cells/μL
- CD4 T-cell count restoration, NK cell activity
- CD4 increased 28%, NK cytotoxicity increased 35%
- 12 weeks at 1.6mg twice weekly
- Immune reconstitution post-chemotherapy is the primary benefit—direct antitumor effects remain under investigation
- Chronic Fatigue with Immune Dysregulation
- Low NK cell activity, Th2-dominant cytokine profile
- NK cell function, IFN-gamma production
- NK lysis increased 42%, IFN-gamma increased 38%
- 16 weeks at 1.6mg twice weekly
- Functional immune restoration correlates with symptom improvement in models with documented immune deficiency—effect absent in subjects with normal baseline immunity
- HIV Immunosuppression
- CD4 <200 cells/μL on stable antiretroviral therapy
- CD4 count, CD4/CD8 ratio
- CD4 increased 22%, ratio improved from 0.6 to 0.9
- 20 weeks at 1.6mg twice weekly
- Adjunctive immune restoration therapy—does not replace antiretroviral treatment but supports immune recovery in non-responders
- Post-Surgical Immune Support
- Post-operative lymphopenia (CD4 <400 cells/μL)
- Infection rate, CD4 recovery time
- Infection rate reduced 40%, CD4 recovery 6 days faster
- 8 weeks starting 1 week pre-surgery
- Prophylactic immune support reduces post-operative infections in high-risk surgical populations
- The consistent pattern across research applications: Thymosin Alpha-1 produces the most significant before and after immune changes in subjects with documented immune suppression at baseline. Research models with normal immune function show minimal measurable effects because the peptide modulates rather than stimulates—it restores balance, not elevation beyond normal ranges. Treatment duration matters: most studies show continued immune marker improvement through 12–16 weeks, with plateau effects occurring beyond 20 weeks.